TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (55)	12/16/2000 12:24:11 AM
From: tommysdad	Read Replies (1) of 887

To further clarify, MLNM is in the game because of the Leukosite purchase. Most of the literature and patents out now will be found under the Leukosite brand. Berlex was in the CCR1 small molecule antagonist game early and has published heavily in this area. Take any animal data that comes out of any of these programs with a big ole grain of salt: Berlex reports major species differences for CCR1. Mouse and rat-active compounds may/probably will not translate to human activity. Best models may turn out to be rabbit or marmoset, but this could be pharmacophore-specific. Early days yet. CCR2: Zeneca has patented on polymorphs for diagnosis, so presumably is pursuing. Leukosite/MLNM again, obviously. PNU apparently has a program, though that may not be a small-molecule program. Roche and PFE as RH mentioned. Lots of preliminary activity, but a potentially rich minefield. I suspect many larger companies have exploratory efforts. Don't know about I.P. on assays, etc. It's a new area and I'm not an expert, just an interested observer, so anybody with more info feel free to overrule.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next